This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Multiple sclerosis
  • /
  • Use of anti - interferon beta antibody measurement...
Guideline

Use of anti - interferon beta antibody measurements in multiple sclerosis

Read time: 1 mins
Last updated:29th Jun 2011

The objectives of our task force were to: (i) evaluate differences in immunogenicity of IFN β products; (ii) evaluate the reliability and give recommendations on BABs and NABs assays; (iii) evaluate the impact of NABs on clinical efficacy and give recommendations on the clinical use of measurement of IFN β antibodies; and (iv) review the evidence on prevention of NAB development and the management of patients with NABs.

 

Read full guideline